Advertisement

Loading...

Ascletis Pharma Inc.

1672.HKHKSE
Healthcare
Biotechnology
HK$17.76
HK$1.12(6.73%)
Hong Kong Market is Open • 10:07

Ascletis Pharma Inc. (1672.HK) Stock Competitors & Peer Comparison

See (1672.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1672.HKHK$16.78-0.30%17.6B-55.47-HK$0.30N/A
6160.HKHK$185.80+8.59%257.8B115.17HK$1.49N/A
1801.HKHK$91.45+6.21%146.1B160.19HK$0.53N/A
2269.HKHK$35.24+12.37%136.5B25.21HK$1.31N/A
9926.HKHK$139.70+4.96%119.8B-119.45-HK$1.09N/A
1177.HKHK$6.38+9.06%105.3B39.27HK$0.15+1.53%
1530.HKHK$25.66+5.68%53.4B20.77HK$1.09+1.10%
9995.HKHK$109.90+11.18%52.7B65.62HK$1.46N/A
3759.HKHK$20.82+13.96%51.4B19.40HK$0.97+1.16%
2696.HKHK$75.20+7.97%37.9B40.79HK$1.71N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1672.HK vs 6160.HK Comparison April 2026

1672.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1672.HK stands at 17.6B. In comparison, 6160.HK has a market cap of 257.8B. Regarding current trading prices, 1672.HK is priced at HK$16.78, while 6160.HK trades at HK$185.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1672.HK currently has a P/E ratio of -55.47, whereas 6160.HK's P/E ratio is 115.17. In terms of profitability, 1672.HK's ROE is -0.13%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 1672.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1672.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions